Last reviewed · How we verify
HX575 epoetin alfa (Sandoz)
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.
At a glance
| Generic name | HX575 epoetin alfa (Sandoz) |
|---|---|
| Also known as | Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed® |
| Sponsor | Sandoz |
| Drug class | Erythropoiesis-stimulating agent (ESA) / Biosimilar |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for red blood cell production. By activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation and differentiation, increasing hemoglobin and hematocrit levels. HX575 is a biosimilar formulation developed by Sandoz intended to be therapeutically equivalent to the reference epoetin alfa product.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients undergoing major surgery
Common side effects
- Hypertension
- Thrombotic events (venous thromboembolism, stroke)
- Headache
- Injection site reactions
- Pure red cell aplasia (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HX575 epoetin alfa (Sandoz) CI brief — competitive landscape report
- HX575 epoetin alfa (Sandoz) updates RSS · CI watch RSS
- Sandoz portfolio CI